Helen Rizos
The University of Sydney(AU)Melanoma Institute Australia(AU)Macquarie University(AU)
Publications by Year
Research Areas
Melanoma and MAPK Pathways, Cancer Immunotherapy and Biomarkers, Immunotherapy and Immune Responses, Cutaneous Melanoma Detection and Management, CAR-T cell therapy research
Most-Cited Works
- → Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy(2019)1,005 cited
- → BRAF Inhibitor Resistance Mechanisms in Metastatic Melanoma: Spectrum and Clinical Impact(2014)539 cited
- → Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma(2014)381 cited
- → Circulating Cytokines Predict Immune-Related Toxicity in Melanoma Patients Receiving Anti-PD-1–Based Immunotherapy(2018)358 cited
- → Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms(2015)328 cited
- → Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma(2015)